vTv Therapeutics (VTVT) Fundamentals 2026 — P/E 1566.0x, Revenue Analysis | SniperIQ
vTv Therapeutics (VTVT) is a US-listed Healthcare company in Biotechnology with a market capitalization of $82M, trading at
vTv Therapeutics (VTVT) has a market capitalization of approximately $82M, trading at
vTv Therapeutics's trailing twelve-month P/E ratio is 1566.0x, with a price-to-book (P/B) of 2.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
vTv Therapeutics runs a net profit margin of 6.1%, a gross margin of 100.0%, and an operating margin of -8.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
vTv Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
vTv Therapeutics carries a debt-to-equity ratio of 0.00x and a current ratio of 14.36x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For vTv Therapeutics (VTVT) the key facts are: market cap $82M, P/E 1566.0x, 52-week range 14-44. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Get vTv Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.